Literature DB >> 22989355

Flow cytometric immunophenotyping of regulatory T cells in chronic lymphocytic leukemia: comparative assessment of various markers and use of novel antibody panel with CD127 as alternative to transcription factor FoxP3.

Alakananda Dasgupta1, Manoranjan Mahapatra, Renu Saxena.   

Abstract

This study analyzed the frequency of regulatory T cells (Tregs) in chronic lymphocytic leukemia (CLL) by multiparameter flow cytometric immunophenotyping. Patients showed significantly increased frequencies of Tregs as compared to controls, a significantly higher percentage than that identified by previous studies, possibly indicating a different prognosis of CLL in different parts of the world and, more precisely, a worse prognosis of CLL in the Indian population. A higher frequency of Tregs was also seen in advanced stage of disease with significantly reduced frequencies of Tregs in patients with CLL after chemotherapy. A significant proportion of CD127low/-FoxP3+ Tregs expressed only low levels of CD25. Thus, CD127 appears to be a better marker than CD25 for the identification of CD4+FoxP3+ T cells as potential Tregs. Our results suggest that the specificity and sensitivity of CD4+CD127low/- cells are comparable to those of CD4+FoxP3+, which is the gold standard, and can be used as an alternative. This novel flow cytometric antibody panel with fewer number of antibodies is cost-effective and can be used to enumerate Tregs in resource-limited settings.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22989355     DOI: 10.3109/10428194.2012.730614

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  6 in total

1.  The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.

Authors:  R Thijssen; J Ter Burg; G G W van Bochove; M F M de Rooij; A Kuil; M H Jansen; T W Kuijpers; J W Baars; A Virone-Oddos; M Spaargaren; C Egile; M H J van Oers; E Eldering; M J Kersten; A P Kater
Journal:  Leukemia       Date:  2015-09-04       Impact factor: 11.528

2.  Chronic lymphoproliferative disorders at an Indian tertiary cancer centre - the panel sufficiency in the diagnosis of chronic lymphocytic leukaemia.

Authors:  Geeta V Patil Okaly; Ashwini R Nargund; Venkataswamy E; Prashanth K Jayanna; Chandra Rao Juvva; Shilpa Prabhudesai
Journal:  J Clin Diagn Res       Date:  2013-07-01

3.  Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL.

Authors:  Gonzalo Blanco; Anna Vardi; Anna Puiggros; Andrea Gómez-Llonín; Manuel Muro; María Rodríguez-Rivera; Evangelia Stalika; Eugenia Abella; Eva Gimeno; Manuela López-Sánchez; Alicia Senín; Xavier Calvo; Pau Abrisqueta; Francesc Bosch; Ana Ferrer; Kostas Stamatopoulos; Blanca Espinet
Journal:  Oncoimmunology       Date:  2018-02-20       Impact factor: 8.110

4.  Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients.

Authors:  Kimberly R Kalli; Matthew S Block; Pashtoon M Kasi; Courtney L Erskine; Timothy J Hobday; Allan Dietz; Douglas Padley; Michael P Gustafson; Barath Shreeder; Danell Puglisi-Knutson; Dan W Visscher; Toni K Mangskau; Glynn Wilson; Keith L Knutson
Journal:  Clin Cancer Res       Date:  2018-03-15       Impact factor: 12.531

5.  Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer.

Authors:  Baodan Yu; Junli Wang; Chen He; Wei Wang; Jianli Tang; Runhui Zheng; Chengzhi Zhou; Huanhuan Zhang; Zhiping Fu; Qiasheng Li; Jun Xu
Journal:  Exp Ther Med       Date:  2017-06-08       Impact factor: 2.447

6.  Hookworm Treatment for Relapsing Multiple Sclerosis: A Randomized Double-Blinded Placebo-Controlled Trial.

Authors:  Radu Tanasescu; Christopher R Tench; Cris S Constantinescu; Gary Telford; Sonika Singh; Nanci Frakich; David Onion; Dorothee P Auer; Bruno Gran; Nikos Evangelou; Yasser Falah; Colin Ranshaw; Cinzia Cantacessi; Timothy P Jenkins; David I Pritchard
Journal:  JAMA Neurol       Date:  2020-09-01       Impact factor: 18.302

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.